CRT 2025
Valve and Structural
TAVR Hot Topics Saturday
Sahil Khera, MD, MPH
Interventional Director, Structural Heart Program
Icahn School of Medicine/ The Mount Sinai Hospital
Disclosure(s): Abbott Labs: Consultant (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Edwards Lifesciences LLC: Consultant (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); medtronic.: Consultant (Ongoing), Consulting Fees (e.g., advisory boards) (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing)
Sachin S. Goel, MD, FACC, FSCAI
Medical Director, Structural Heart Interventions
Houston Methodist DeBakey Heart & Vascular Center
Houston, Texas, United States
Disclosure information not submitted.
Jeffrey A. Southard, MD, FACC, FSCAI
Professor of Medicine
Director -TAVR Program
Medical Director- Cath Lab
UC Davis Medical Center
West Sacramento, California, United States
Disclosure(s): Abbott Cardiovascular Systems: Consulting Fees (e.g., advisory boards) (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Boston Scietific: Grant/Research Support (Ongoing); Edward Lifesciences: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Shockwave Medical: Consulting Fees (e.g., advisory boards) (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing)
Andreas Baumbach, MD, FRCP, FESC
Chair
Queen Mary University of London
London, England, United Kingdom
Disclosure information not submitted.
Joao L. Cavalcante, MD, FACC
Director, Cardiac MRI, Structural CT and Cardiovascular Core Lab Imaging
Minneapolis Heart Institute
Minneapolis, Minnesota, United States
Disclosure(s): 4C Medical, Abbott Structural, Alleviant, Anteris, Boston Scientific, Edwards Lifesciences, JenaValve, JC Medical, Medtronic, Novo Nordisk, Siemens Healthineers, VDyne, Zoll: Consultant (Ongoing), Consulting Fees (e.g., advisory boards) (Ongoing)
Tsuyoshi Kaneko, MD
Chief of Cardiac Surgery Section
Washington University in St. Louis
Disclosure(s): 4C Medical Technologies, Inc.: Consulting Fees (e.g., advisory boards) (Ongoing); Abbott Vascular, Medtronic, Boston Scientific: Consulting Fees (e.g., advisory boards) (Ongoing); Anteris: Consulting Fees (e.g., advisory boards) (Ongoing); Edwards Lifesciences: Consulting Fees (e.g., advisory boards) (Ongoing); Johnson and Johnson: Consulting Fees (e.g., advisory boards) (Ongoing); Medtronic, Inc.: Consulting Fees (e.g., advisory boards) (Ongoing)
Azeem Latib, MD
Director, Interventional Cardiology & Structural Heart Interventions
Montefiore Medical Center
Scarsdale, New York, United States
Disclosure(s): Boston Scientific, Metronic: Consulting Fees (e.g., advisory boards) (Ongoing)
Konstantinos Marmagkiolis, MD,MBA,FACC,FSCAI
interventional, structural, and endovascular cardiologist
Heart and Vascular Institute (HVI) at Tampa General Hospital (TGH) in Tampa, FL
Wesley Chapel, Florida, United States
Disclosure(s): No financial relationships to disclose
Vinod Thourani, MD, FACC, FACS
Professor of Surgery, Chairman of Cardiovascular Surgery
Piedmont Heart Institute
Atlanta, Georgia, United States
Disclosure(s): Abbott Labs: Consultant (Ongoing), Grant/Research Support (Ongoing); boston scientific: Grant/Research Support (Ongoing); Croivalve: Consultant (Ongoing), Grant/Research Support (Ongoing); DASI Simulations: Consultant (Ongoing), Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (Ongoing); Edward Lifesciences: Consultant (Ongoing), Grant/Research Support (Ongoing); JenaValve Technology Inc: Consultant (Ongoing), Grant/Research Support (Ongoing); Laplace: Grant/Research Support (Ongoing); medtronic.: Grant/Research Support (Ongoing); trisol: Grant/Research Support (Ongoing), Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (Ongoing)